Prowill Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.16 Cr
as on 15-11-2024
- Paid Up Capital ₹ 4.75 Cr
as on 15-11-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 46.93%
(FY 2023)
- Profit 115.02%
(FY 2023)
- Ebitda 182.50%
(FY 2023)
- Net Worth 25.50%
(FY 2023)
- Total Assets 14.57%
(FY 2023)
About Prowill Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.16 Cr and a paid-up capital of Rs 4.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Santosh Joshi and Varsha Joshi serve as directors at the Company.
- CIN/LLPIN
U74999MH2012PTC229057
- Company No.
229057
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Mar 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNavi Mumbai, Maharashtra
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Prowill Pharmaceuticals Private Limited offer?
Prowill Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Injectable Products, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Brain & Nervous System Drugs, Immunomodulator Drugs, Sexual Wellness Products, Contraceptives, Nutraceuticals & Dietary Supplements.
Who are the key members and board of directors at Prowill Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Santosh Joshi  | Director | 30-Mar-2012 | Current |
| Varsha Joshi | Director | 18-Jul-2022 | Current |
Financial Performance of Prowill Pharmaceuticals.
Prowill Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 46.93% increase. The company also saw a substantial improvement in profitability, with a 115.02% increase in profit. The company's net worth Soared by an impressive increase of 25.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Prowill Pharmaceuticals?
In 2023, Prowill Pharmaceuticals had a promoter holding of 82.69% and a public holding of 17.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Allcure Health Care Private LimitedActive 14 years 3 monthsSantosh Joshi and Varsha Joshi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Prowill Pharmaceuticals?
Prowill Pharmaceuticals has a workforce of 9 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Prowill Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Prowill Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
